Remove 2002 Remove Cannabinoids Remove Clinical Trials Remove Data
article thumbnail

New Study: Demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use: an analysis of the 2013–2017 Traffic Safety Culture Index

Cannabis Law Report

Studies of crash or driving data suggest that, although permissive marijuana policies are associated with higher prevalence of tetrahydrocannabinol (THC) presence among drivers [ 1 , 2 ], there is mixed evidence that these policies are associated with motor vehicle crashes [ 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. never vs. at least once). (2)

Policy 59
article thumbnail

NO BRAINER: CBD AND THC FOR HEAD INJURIES

Green Relief

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Green Relief - Untitled Article

Green Relief

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

At the same time, the outlook on cannabis research data is largely positive. The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Data collection. Bonini et al. 2016 ; Sznitman et al. years (Atakan 2012 ).

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.